Background: Nasopharyngeal carcinoma constitutescomprises up to 5% of primary childhood cancers but literature lacks modern uniformly treated large series.
Introduction
Nasopharyngeal carcinoma accounts for around l % -5 % of all primary cancers in children and less than 30% of nasopharyngeal cancers [1] [2] [3] . The undifferentiated variant of the disease is the most common, and is closely related to a higher rate of advanced locoregional disease and metastasis [1, [3] [4] [5] [6] [7] [8] [9] . However, the five-year diseasefree survival rate is 29%-60%, which is not significantly different from that in adults [6, [10] [11] [12] , and standard therapy has generally followed the guidelines established for adults. Unfortunately, high-dose radiation in children has been associated with significant morbidity among long-term survivors [5, 8, 13, 14] . This paper describes our 13-year experience in 65 children with nasopharyngeal carcinoma with the aim of contributing to the epidemiological, therapeutical and clinical aspects of this disease.
Patients and methods
Between January 1980 and December 1993. 1920 patients were treated for nasopharyngeal carcinomas at the Ibn Rochd Oncology Centre in Casablanca. We reviewed only the 65 of them who were under 16 years of age. The histological diagnosis was made in all cases according to the World Health Organisation (WHO) classification. The extent of disease was determined by complete clinical examination using direct nasopharyngoscopy until 1990, and thereafter direct flexible or rigid nasopharyngoscopy. In addition, standard radiography of the nasopharynx was performed in patients treated before 1989. Since 1989, these were complemented by computed tomography (CT) scans. Chest radiography and liver ultasonography were done in all patients. Scinligraphy was performed in three patients treated after 1992 and standard radiography of bone was performed in one patient because of bone pain.
TheTNM classification system of the UICC was used to define the extent of disease. The classification was retrospective in the first 20 patients and prospective in the remaining ones (Table 1 ). All patients received radiotherapy using cobalt (C06O). The primary tumour was treated with two opposed lateral fields. The margins included the nasopharynx, the oropharynx and the upper neck and base of the skull in T 4 tumours. A third anterior field was used in four patients who had nasal extension. A total dose of 60-70 Gy was administered in daily fractions of 2 Gy five days a week and 36 patients received a dose 5 65 Gy. The lower cervical and supraclavicular regions were treated with a single anterior portal and a median shield to protect the larynx and the spinal cord with doses at 45 Gy. Clinically involved neck areas were boosted with two opposed fields to doses of 60-65 Gy. Chemotherapy was introduced early and 31 patients received neo-adjuvant treatment. Between 1980 and 1991 the chemotherapy included cyclophosphamide (400 mg/m 2 day 1-5). Following 1991, patients received chemotherapy 36 (69) 16 (31) 10 (19) 24 (46) 18 (35) 10 (19) 42 (81) 30 (58) 22 (42) 22 (42) 30 ( . The average number of cycles was 3. Treatment was continued by radiotherapy four weeks after the end of chemotherapy, with the same dose and technique as described before.
The survival curves were calculated by the Kaplan-Meier method. The differences between the curves were compared by log-rank test and the Chi-square test was used for testing the difference between prognostic factors.
Results
This series of 65 children under 16 years old comprises approximately 3.5% of all the cases of nasopharyngeal carcinoma treated at our institution. The median age at diagnosis was 10 years with a range of 7-15 years and 65% of patients were ^ 13 years of age. There were 44 boys and 21 girls, with a male to female ratio of 2:1 consistent in all age classes.
Over time, 13 children were lost to follow-up, so failures, survival and disease-free survival at 5 years were analysed only for the remaining 52 patients. Table 2 summarises the characteristics of patients and their outcome. Local control was obtained in 85% of cases. The five-year survival was 42% and the disease-free survival was 38% (Figure 1 ). Ten relapses (30%) occurred at local and/or regional sites, only four of which were local. There were six relapses at distant metastatic sites. Sites of distant metastasis were bone (three patients) and liver (one patient). The remaining two relapses included both distant and locoregional sites. The time to first relapse was 6-46 months with 50% of first relapses occurring within the first year. None of the patients who relapsed was salvaged despite additional radiation therapy and/or chemotherapy. When relapse and failure/persistent disease are considered together, the distribution of 24 patients with relapse and persistent disease by T-stage yielded 19 patients withT 34 disease. Similarly, 21 of the ) and disease-free ( ) survival curves.
Years patients with relapse and persistent disease were in N3 stage and 14 patients have an epidermoid carcinoma. Persistent disease or relapse occurred in 16 patients who were treated by radiation alone versus 8 patients treated by chemotherapy followed by radiotherapy. A total of 24 patients had died by the fifth year of follow-up. Six died with distant metastasis, four of whom had no evidence of associated local relapse or regional relapse. Ten patients died with distant metastasis after local or regional relapse and eight after failure/persistent disease.
The five-year survival rate for males was 38% compared with 48% for females (P =0.1). The TNM stage is an important predictor of outcome: the five-year survival of patients with T 3>4 -No,i was 69%, for patients withT,_ 2 , N 2 -3 58% and 28% ' for patients with T 3 _ 4 , N 2 _ 3 (P < 0.001). The five-year survival rate was significantly better for patients with undifferentiated carcinoma (Table 2) . For patients treated with irradiation, the fiveyear survival rate was 39% for those receiving more than 65 Gy and 45% for those receiving less than 65 Gy (P < 0.001). There was a statistically significant difference between the survival rates of patients who were treated with irradiation only and those who received chemotherapy followed by radiotherapy (P < 0.001).
Acute radiation toxicity, which included mucositis or reaction in 75% of the patients, was tolerable. Over the long term, the dominant complications were a cervical sclerosis in 25 cases and dental damage in 15 cases. Neuroendocrine evaluations were assessed in 10 cases, revealing a biological hypothyroidism in 5 cases treated medically. Hearing deficit occurred in nine cases. Three patients recovered from xerostomia of more than two years'duration.
Discussion
The incidence of childhood nasopharyngeal carcinoma varies widely according to racial and geographical factors. In the child it most commonly presents as advanced locoregional disease. Many series report that 15% or fewer of nasopharyngeal carcinomas in pediatric patients are at an early stage (T1.2-N0.1) at the time of diagnosis and that advanced T or N stage has been associated with a high rate of distant metastasis [1, 4, 7, 13, [15] [16] [17] . In our series, stages T 1 2 -N 0 1 were found in 18.5% and 96% of the patients had palpable lymph nodes. However, the overall survival rates are not significantly different between children and adults with nasopharyngeal carcinoma. The five-year disease-free survival rate is 38% in our series which is within the 29%-60% range reported in paediatric series [5-7, 12, 18] . Staging has been a prognostic aid in patients with nasopharyngeal carcinoma, with advanced Tor N stages reported to be associated with adverse outcome [6, 12, 16, 19] . Because the majority of patients in this series had T34 and/or N 3 disease, comparison for outcome between T and N stages would not be feasible. Analysis of the five-year survival for our patients indicates that stages T or N and histological type were significant.
Standard therapy for nasopharyngeal carcinoma in children has generally followed the guidelines established for adults, which consist of high-dose radiation to nasopharynx and involved cervical node areas as well as moderate doses to uninvolved cervical node sites. The total dose to the tumour appears to be an important prognostic factor for adults, but the significance of dose for survival is less clear in paediatric patients. Although high-dose radiotherapy in children can be curative it has been associated with significant morbidity among longterm survivors [2, 6, 7, 10, 13, 20] . However, a higher dose may improve the local control [6, 21] , Ingersoll [6] reports a better control of patients treated by radiotherapy with doses greater than 65 Gy. Ayan [4] reports no major differences between treatment groups in radiation technique and doses at the median dose was 62 Gy, but it was observed that ultimate local control improved with total doses exceeding 60 Gy. Some authors [5, 7, 15, 18] report more local relapses outside and within borders of radiation fields. Labo-Sanahuja [22] and Lombardi [12] report having found no correlation among radiation dose, local relapse and survival time. Berry [18] and Jenkin [15] note that local control could be obtained with the radiation dose of 35-65 Gy. At present, a dose between 62-66 Gy in the initial tumour volume is recommended for children older than 10 years and 5%-10% less for the children of less than 10 years [6] . The major obstacle to the cure of childhood nasopharyngeal carcinoma is distant metastasis. There is a clear need for early, effective systemic treatment, but it is uncertain whether current chemotherapeutic agents can fulfil the promise of eradicating occult metastases [23] [24] [25] [26] [27] ; the number of patients in each series was small and only a few were randomised. In the adult literature, clinical trials for advanced tumors evaluating the use of chemoradiotherapy should be considered [28, 29] . Two randomized prospective trials compared combination chemotherapy plus radiotherapy to radiotherapy alone [30, 31] . Although disease-free survival was improved in the chemotherapy groups of both series, improvement in overall survival was reported only in the one from the intergroup study 0099 [30] . In our series, there is a suggestion that the pediatric patients who had chemotherapy before radiation did better than those who were treated by radiation alone. Ingersoll [6] reported encouraging results in 14 young adults treated with chemotherapy before radiation. The durations of relapse-free time ranged from 6 months to 23 years. For Gasparini [32] , the three-year relapse-free survival rate was 75% for children treated by neo-adjuvant chemotherapy as opposed to 8% in the group treated with radiation therapy alone. In this series all of the children had stages T34. Kim [33] also reported good results in 7 children treated with combination chemotherapy 12-24 months following radiation therapy. The relapse-free survival rate was 86% with a follow-up ranging from 22 months to 12 years. Ghim [20] obtained local control in 9 of 12 patients aged between 6 and 20 years treated for locally advanced or metastastatic stages by radiation therapy after chemotherapy. Local control was obtained in 9 cases with a median of 11 years of follow-up. In the Ingersoll series [6] , only one of 14 patients who received combined radiotherapy and chemotherapy relapsed locally. Distant metastasis remains the major pattern of failure in nasopharyngeal carcinoma [5, 6, 11, 12] and our results in the combined treatment group are in keeping with this observation.
Reports of long-term results including late effects of treatment in children with nasopharyngeal carcinoma are rare. Late endocrine effects manifested by stunted growth, thyroid dysfunction, and soft tissue fibrosis, bone and dental problems have been reported as a consequence of high-dose radiotherapy [6, 7, 13, 15, [32] [33] [34] [35] . Dental complications have been noted in 15 children in our study. Second malignancies have been reported as a consequence of high-dose radiotherapy with or without chemotherapy [5, 6, 12, 15, 36] . Ayan [4] reports 3 of 48 treated patients who developed second malignant tumours, occurring either within or outside the radiation field after a median of 77 months. Ingersoll [6] reports 3 cases of secondary cancer among 57 children treated, two of whom received chemotherapy after 6 and 11 years.
In conclusion, the results of our retrospective analysis of children with nasopharyngeal carcinoma appear comparable to those reported in the literature. There is evidence that this tumour is chemosensitive and that neoadjuvant chemotherapy may be effective. Indeed, the disease-free survival ranges from 75%-100% in several series after chemotherapy. However, because of the rarity of nasopharyngeal carcinoma, conclusive data on the impact of chemotherapy cannot be collected without co-operative studies. New strategies for prevention, and more effective and less toxic treatment should be developed.
